[The polycentric multiple arc complanar technic, or telebrachytherapy. A 4-year experience (an innovative way for the local control of solid XXXX )].

@entity1 @entity135 @entity137 @entity4318 @entity242 @entity1313 @entity5 @entity2 @entity4515 @entity418 @entity1282 @entity1893 @entity4434
The coplanar polycentric multiple 180 degrees single arc and narrow beams technique ( @entity4515 ) allows high radiation doses to be delivered to the target, with similar dose distribution to that of brachytherapy. Since 1990, more than 100 @entity1 have been treated: 80 had NSCLC, 12 had epidermoid head and neck (oral cavity and oropharynx) @entity5 , 8 @entity1313 , 4 @entity418 and, sporadically, other @entity1 had many other kinds of @entity5 , e.g., @entity1893 and @entity242 . X photons of a 12-MV Linac have always been used. NSCLC @entity1 are assessable for local control, @entity137 and survival, while the other @entity1 only for local control and/or @entity137 . As for 31 stage I-II @entity2 @entity1 , CR has been observed in 82.8% of them and PR in 13.8%; the response was always assessed with chest radiography, CT, @entity4434 , cytology and/or histology. The overall actuarial survival rate is 71% at 40 months, the disease-free survival rate is 75% and the local progression-free survival rate is 94%. As for 49 stage-III @entity1 , CR has been observed in 40% of them and PR in 56%. The overall disease-free survival is 10% at 28 months (median survival: 14.37 +/- 0.6 months). The disease-free survival rate @entity4318 %. The local progression-free survival rate is similar to the overall survival rate, which seems to prove the very high metastatic spread of this disease in advanced stages. Twelve @entity135 @entity1 have been treated, 5 of them in stage II and 7 in stage IV. CR has been observed in all the @entity1 in lower stages (100%), in 4/7 @entity1 in stage IV (57%) and in 4/5 @entity1 (80%) in the T4N0 subgroup. The response of @entity1313 treated with the @entity4515 technique is difficult to assess because radiographic, CT and MR images are difficult to correlate with @entity1 clinical status. The @entity1 in our series are still alive, with a medium follow-up of 7 months (range: 2-16 months). A longer follow-up is necessary before any other considerations on the effectiveness of this method can be made. This technique was used on the @entity1 who were not eligible for the other techniques with high doses delivered to the @entity5 , because of its volume and/or shape. Four @entity418 were treated with palliative intent, because of @entity1282 , in alternative to HDR brachytherapy. All these @entity1 have obtained symptom remission.(ABSTRACT TRUNCATED AT 400 WORDS)
